 |
|
|
| |
A phase 1 trial of N-803 with or without dual bNAbs to achieve ART-free viral control: ACTG A5386
|
| |
| |
CROI 2026 Feb 22-25 Denver
Jones RB1, Mar H2, Scheck R1, Miller I1, Venuto CS3, DiFrancesco R4, Freeman ML5, Cyktor JC6, Ward A1, Mellors JW6, Morse GD3, Tressler R7, Bosch RJ2, Caskey M8, Wilkin T9
1Weill Cornell Medicine, NY, USA, 2Harvard TH Chan School of Public Health, MA, USA, 3University of Rochester, NY, USA,4University of North Carolina Chapel Hill, NC, USA 5Case Western Reserve University School of Medicine, OH, USA, 6University of Pittsburgh, PA, USA 7National Institutes of Health, MD, USA, 8The Rockefeller University, NY, USA, 9University of California San Diego, CA, USA
|
| |
|
|
|
|
|
